Sign in

CIK 0001664710

  • Non-accelerated filer
  • Smaller reporting company

Keros Therapeutics, Inc.

Sign in to watch
Ticker
KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
811173868
Phone
+1 617-314-6297
Business address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
  1. 4 Open-market sale Chief Scientific Officer sold 2,650 shares at an average $52.06 ($137,965)
  2. 4 Derivatives Options or other derivatives
  3. 3 Insider Initial Statement of Ownership
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Open-market sale Chief Scientific Officer sold 2,650 shares at an average $53.75 ($142,447)
  9. 4 Open-market sale Chief Scientific Officer sold 2,650 shares at $60.00 ($159,000)
  10. 4 Open-market sale Director sold 47,651 shares at an average $57.84 ($2,756,116)
  11. 4 Open-market sale Chief Scientific Officer sold 2,650 shares at an average $50.40 ($133,558)
  12. 4 Open-market sale Director sold 47,651 shares at an average $54.09 ($2,577,376)
  13. 4 Open-market sale Chief Scientific Officer sold 21,200 shares at an average $59.91 ($1,270,058)
  14. 4 Open-market sale Chief Scientific Officer sold 10,600 shares at $50.00 ($530,000)
  15. 4 Open-market sale Director sold 47,651 shares at an average $42.12 ($2,007,129)
  16. 4 Open-market sale Director sold 8,598 shares at an average $38.20 ($328,441)
  17. 4 Open-market sale Director sold 26,367 shares at an average $38.56 ($1,016,653)
  18. 4 Open-market sale Director sold 12,686 shares at an average $40.10 ($508,755)
  19. 4 Open-market sale Director sold 95,302 shares at an average $41.17 ($3,924,003)
  20. 4 Option exercise Chief Scientific Officer acquired 1,293 shares (option exercise)

Page 7 of 11 · 207 filings